[go: up one dir, main page]

EA201890754A1 - Соединения и способы их применения - Google Patents

Соединения и способы их применения

Info

Publication number
EA201890754A1
EA201890754A1 EA201890754A EA201890754A EA201890754A1 EA 201890754 A1 EA201890754 A1 EA 201890754A1 EA 201890754 A EA201890754 A EA 201890754A EA 201890754 A EA201890754 A EA 201890754A EA 201890754 A1 EA201890754 A1 EA 201890754A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
connections
application
compounds
inhibit glutaminase
Prior art date
Application number
EA201890754A
Other languages
English (en)
Inventor
Рене М. Лемье
Джанета Поповичи-Мюллер
Франческо Г. Салитуро
Джеффри О. Сондерз
Джереми М. Трэвинс
Юншэн Чэнь
Original Assignee
Аджиос Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аджиос Фармасьютикалз, Инк. filed Critical Аджиос Фармасьютикалз, Инк.
Publication of EA201890754A1 publication Critical patent/EA201890754A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

В данном документе описаны соединения и композиции, содержащие соединения, которые ингибируют глутаминазу. Также в данном документе описаны способы применения соединений, которые ингибируют глутаминазу, при лечении рака.
EA201890754A 2012-11-22 2013-11-21 Соединения и способы их применения EA201890754A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof

Publications (1)

Publication Number Publication Date
EA201890754A1 true EA201890754A1 (ru) 2018-08-31

Family

ID=50775393

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590987A EA030646B1 (ru) 2012-11-22 2013-11-21 Соединения и способы их применения
EA201890754A EA201890754A1 (ru) 2012-11-22 2013-11-21 Соединения и способы их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201590987A EA030646B1 (ru) 2012-11-22 2013-11-21 Соединения и способы их применения

Country Status (36)

Country Link
US (2) US10087172B2 (ru)
EP (2) EP3456719A1 (ru)
JP (2) JP6333277B2 (ru)
KR (1) KR20150085079A (ru)
CN (2) CN108727307A (ru)
AR (1) AR093598A1 (ru)
AU (2) AU2013347771B2 (ru)
BR (1) BR112015011830A2 (ru)
CA (1) CA2893510C (ru)
CL (1) CL2015001392A1 (ru)
CR (1) CR20150316A (ru)
CY (1) CY1120581T1 (ru)
DK (1) DK2922850T3 (ru)
EA (2) EA030646B1 (ru)
EC (1) ECSP15026557A (ru)
ES (1) ES2690390T3 (ru)
HR (1) HRP20181628T1 (ru)
HU (1) HUE040111T2 (ru)
IL (1) IL238958B (ru)
LT (1) LT2922850T (ru)
MX (1) MX367389B (ru)
MY (1) MY177344A (ru)
NZ (1) NZ708382A (ru)
PE (1) PE20151072A1 (ru)
PH (2) PH12015501150B1 (ru)
PL (1) PL2922850T3 (ru)
PT (1) PT2922850T (ru)
RS (1) RS57859B1 (ru)
SA (1) SA515360469B1 (ru)
SG (2) SG10201609940RA (ru)
SI (1) SI2922850T1 (ru)
SM (1) SMT201800504T1 (ru)
TR (1) TR201812360T4 (ru)
TW (2) TW201906825A (ru)
UA (1) UA117360C2 (ru)
WO (3) WO2014079011A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
CN105051041B (zh) 2012-11-16 2018-03-30 卡利泰拉生物科技公司 杂环谷氨酰胺酶抑制剂
EP2922832B1 (en) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
EP2925318A4 (en) * 2012-12-03 2016-07-13 Calithera Biosciences Inc TREATMENT OF CANCER WITH HETEROCYCLIC GLUTAMINASE INHIBITORS
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
CN108715590B (zh) 2013-01-15 2022-03-08 因赛特公司 可用作pim激酶抑制剂的噻唑甲酰胺和吡啶甲酰胺化合物
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
CN112920180A (zh) 2014-01-06 2021-06-08 理森制药股份公司 谷氨酰胺酶抑制剂
CN106231900B (zh) 2014-03-21 2019-05-28 阿吉奥斯制药公司 化合物及其使用方法
HRP20192056T1 (hr) * 2014-04-30 2020-02-21 Pfizer Inc. Derivati diheterocikla vezani na cikloalkil
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
HUE049600T2 (hu) 2014-07-03 2020-10-28 Univ Texas GLS1 inhibitorok betegségek kezelésére
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
AU2015300825B2 (en) 2014-08-07 2019-10-10 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) * 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
EP3280415A4 (en) 2015-04-06 2018-12-26 Calithera Biosciences Inc. Treatment of lung cancer with inhibitors of glutaminase
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
EP3316887B1 (en) * 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1 inhibitors for treating disease
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP6971239B2 (ja) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN109503570B (zh) * 2015-12-18 2020-08-25 诺言医药科技(上海)有限公司 一种含有索拉非尼的药物组合物及其应用
KR102777513B1 (ko) 2015-12-22 2025-03-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 (ｒ)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-ｎ-메틸-1ｈ-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
SG11201901389XA (en) * 2016-08-25 2019-03-28 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
JP7361687B2 (ja) 2017-10-18 2023-10-16 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム グルタミナーゼ阻害薬療法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
US20210403479A1 (en) 2018-11-08 2021-12-30 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
ES2152310T3 (es) 1993-03-29 2001-02-01 Basf Ag Derivados de 1-amino-3-fenoxipropano como moduladores de la resistencia a multiples a farmacos.
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
WO1999065884A1 (en) 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
WO2001062206A2 (en) 2000-02-22 2001-08-30 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2008048967A1 (en) 2006-10-16 2008-04-24 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
AU2008326497B2 (en) 2007-11-19 2014-02-13 Genentech, Inc. Compositions and methods for inhibiting tumor progression
JP2011516826A (ja) 2008-03-07 2011-05-26 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 間葉系様腫瘍細胞またはこの形成を阻害する作用剤の同定のための方法
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US10532034B2 (en) 2009-03-25 2020-01-14 Cornell University Inhibition of glutaminase C
US20120142028A1 (en) 2009-04-17 2012-06-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
AU2011270968C1 (en) 2010-06-23 2017-01-19 University Of Louisville Research Foundation, Inc. Methods for detecting cancer
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
KR20190127971A (ko) * 2011-11-21 2019-11-13 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제의 헤테로사이클릭 억제제
EP2844270A4 (en) 2012-03-15 2016-01-27 Univ New York State Res Found COMBINATION THERAPIES WITH INHIBITORS OF THE EXTRACELLULAR DOMAIN OF E-CADHERINE
EP2922832B1 (en) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
CN112920180A (zh) 2014-01-06 2021-06-08 理森制药股份公司 谷氨酰胺酶抑制剂
CN106231900B (zh) 2014-03-21 2019-05-28 阿吉奥斯制药公司 化合物及其使用方法

Also Published As

Publication number Publication date
PH12017502141A1 (en) 2019-02-27
EA030646B1 (ru) 2018-09-28
EP3456719A1 (en) 2019-03-20
BR112015011830A2 (pt) 2017-07-11
CN104936954A (zh) 2015-09-23
PH12015501150A1 (en) 2015-08-17
CL2015001392A1 (es) 2016-04-22
PT2922850T (pt) 2018-10-15
HRP20181628T1 (hr) 2018-12-14
EP2922850A1 (en) 2015-09-30
SG10201609940RA (en) 2016-12-29
RS57859B1 (sr) 2018-12-31
US20190084976A1 (en) 2019-03-21
US10689375B2 (en) 2020-06-23
US10087172B2 (en) 2018-10-02
ECSP15026557A (es) 2016-01-29
HK1214593A1 (en) 2016-07-29
EP2922850A4 (en) 2016-05-18
JP6333277B2 (ja) 2018-05-30
SMT201800504T1 (it) 2018-11-09
LT2922850T (lt) 2018-09-10
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
US20150291576A1 (en) 2015-10-15
EA201590987A1 (ru) 2015-12-30
WO2014079150A1 (en) 2014-05-30
CR20150316A (es) 2015-08-28
PE20151072A1 (es) 2015-08-26
MY177344A (en) 2020-09-13
MX367389B (es) 2019-08-19
TW201427963A (zh) 2014-07-16
TW201906825A (zh) 2019-02-16
NZ708382A (en) 2020-04-24
CA2893510C (en) 2021-01-19
DK2922850T3 (en) 2018-10-08
CA2893510A1 (en) 2014-05-30
IL238958A0 (en) 2015-07-30
CN108727307A (zh) 2018-11-02
JP2018150316A (ja) 2018-09-27
TWI629268B (zh) 2018-07-11
AU2013347771B2 (en) 2018-02-01
AU2018202954A1 (en) 2018-05-17
PH12015501150B1 (en) 2018-05-04
UA117360C2 (uk) 2018-07-25
WO2014079011A1 (en) 2014-05-30
AR093598A1 (es) 2015-06-10
SG11201504049VA (en) 2015-07-30
PL2922850T3 (pl) 2018-12-31
SA515360469B1 (ar) 2017-07-11
JP2016500082A (ja) 2016-01-07
CY1120581T1 (el) 2019-07-10
CN104936954B (zh) 2018-08-14
IL238958B (en) 2019-09-26
EP2922850B1 (en) 2018-07-18
WO2014079136A1 (en) 2014-05-30
TR201812360T4 (tr) 2018-09-21
AU2013347771A1 (en) 2015-06-11
ES2690390T3 (es) 2018-11-20
SI2922850T1 (sl) 2018-10-30
HUE040111T2 (hu) 2019-02-28

Similar Documents

Publication Publication Date Title
EA201890754A1 (ru) Соединения и способы их применения
EA201590997A1 (ru) Соединения и способы их применения
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1120035T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201691114A1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
EA201400178A1 (ru) Лечение рака молочной железы
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201300171A1 (ru) Способы и композиции для терапии рака печени
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
EA201201000A1 (ru) Способы лечения колоректального рака
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений